Page 13 - Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma

CUAJ – Consensus Statement Mason et al
KCRNC consensus: Cytoreductive nephrectomy for mRCC

32. Tatokoro M, Saito K, Iimura Y, Fujii Y, Kawakami S, Kihara K. Prognostic
impact of postoperative C-reactive protein level in patients with metastatic renal
cell carcinoma undergoing cytoreductive nephrectomy. J Urol. 2008;180:515-9.
33. Marconi L, de Bruijn R, van Werkhoven E, Beisland C, Fife K, Heidenreich A, et
al. External validation of a predictive model of survival after cytoreductive
nephrectomy for metastatic renal cell carcinoma. World journal of urology. 2018.
34. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a
comparative treatment for clinical trials of new therapies against advanced renal
cell carcinoma. Journal of clinical oncology : official journal of the American
Society of Clinical Oncology. 2002;20:289-96.
35. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al.
Prognostic factors for overall survival in patients with metastatic renal cell
carcinoma treated with vascular endothelial growth factor-targeted agents: results
from a large, multicenter study. Journal of clinical oncology : official journal of
the American Society of Clinical Oncology. 2009;27:5794-9.
36. Bex A, Albiges L, Ljungberg B, Bensalah K, Dabestani S, Giles RH, et al.
Updated European Association of Urology Guidelines for Cytoreductive
Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell
Carcinoma. European urology. 2018;74:805-9.
37. Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, et al. The
outcome of patients treated with sunitinib prior to planned nephrectomy in
metastatic clear cell renal cancer. Eur Urol. 2011;60:448-54.
38. Powles T, Sarwar N, Stockdale A, Sarker S-J, Boleti E, Protheroe A, et al. Safety
and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic
Clear Cell Renal Cancer. JAMA Oncol. 2016;2:1303-9.
39. Kutikov A, Uzzo RG, Caraway A, Reese CT, Egleston BL, Chen DY, et al. Use
of systemic therapy and factors affecting survival for patients undergoing
cytoreductive nephrectomy. BJU international. 2010;106:218-23.
40. Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P, Jonasch E, et al. Primary
tumor response to targeted agents in patients with metastatic renal cell carcinoma.
Eur Urol. 2011;59:10-5.
41. Hellenthal NJ, Mansour AM, Hayn MH, Schwaab T. Is there a role for partial
nephrectomy in patients with metastatic renal cell carcinoma? Urol. 2013;31:36-
41.
42. Lane BR, Derweesh IH, Kim HL, O'Malley R, Klink J, Ercole CE, et al.
Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in
patients with renal cell carcinoma. Urologic Oncology: Seminars and Original
Investigations. 2015;33:112.e15-.e21.